Imagion Biosystems Limited provided this update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging agent. The study is intended to investigate the potential for the MagSense® HER2 targeted imaging agent to be used for nodal staging of HER2 positive breast cancer by detecting if tumour cells have metastasized to the
lymph nodes. Currently, nodal staging requires a patient's lymph nodes to be surgically biopsied for histopathological examination. Based on the observations to date, the Company plans to move forward with scale-up activities to support
further development and clinical studies that would support regulatory submissions. If one of the imaging methods is shown to be effective in pivotal studies, the MagSense® HER2 test would be commercialized as a non-invasive alternative reducing the need for biopsies for nodal staging.